mRNA-1345 Market Size, Forecast, and Emerging Insight - 2032

“mRNA-1345 Market Size, Forecast, and Emerging Insight - 2032” report provides comprehensive insights about mRNA-1345 for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the mRNA-1345 for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the mRNA-1345 for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the mRNA-1345 market forecast analysis for RSV in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.

Drug Summary

The mRNA-1345 vaccine is a messenger RNA (mRNA) vaccine. This mRNA is entirely made in a laboratory and instructs the body to build small pieces of proteins. Moderna’s mRNA-1345 RSV vaccine candidate encodes for a prefusion F glycoprotein, eliciting a superior neutralizing antibody response.

In this case, the vaccine candidate contains the mRNA code for the RSV glycoprotein F, which does not cause RSV infection but helps the body’s immune system recognize and protect itself if it encounters the virus. Therefore, one cannot become infected with RSV by receiving the investigational vaccine. The mRNA-1345 RSV vaccine candidate prevents illness from RSV, a leading cause of respiratory illness in young and older adults (65+). Currently, the drug is in Phase III for older adults. mRNA-1345 is also ongoing in a Phase I trial in pediatric populations; RSV is also a large burden in the pediatric population.

RSV program has endorsed the start of the Phase III portion of the pivotal clinical study of mRNA-1345, the Company's Respiratory Syncytial Virus (RSV) vaccine candidate, in adults 60 years and older. The DSMB's endorsement comes after independent review of preliminary Phase II data, which suggest that the vaccine has an acceptable safety profile in older adults at the selected dose. This study is known as ConquerRSV.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the mRNA-1345 description, mechanism of action, dosage and administration, research and development activities in Respiratory syncytial virus (RSV).
• Elaborated details on mRNA-1345 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the mRNA-1345 research and development activities in RSV across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around mRNA-1345.
• The report contains forecasted sales of mRNA-1345 for RSV till 2032.
• Comprehensive coverage of the late-stage emerging therapies for RSV.
• The report also features the SWOT analysis with analyst views for mRNA-1345 in RSV.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

mRNA-1345 Analytical Perspective

In-depth mRNA-1345 Market Assessment

This report provides a detailed market assessment of mRNA-1345 for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

mRNA-1345 Clinical Assessment

The report provides the clinical trials information of mRNA-1345 for RSV covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Respiratory syncytial virus (RSV) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence mRNA-1345 dominance.
• Other emerging products for RSV are expected to give tough market competition to mRNA-1345 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of mRNA-1345 in RSV.
• Our in-depth analysis of the forecasted sales data of mRNA-1345 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the mRNA-1345 in RSV.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of mRNA-1345?
• What is the clinical trial status of the study related to mRNA-1345 in Respiratory syncytial virus (RSV) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the mRNA-1345 development?
• What are the key designations that have been granted to mRNA-1345 for RSV?
• What is the forecasted market scenario of mRNA-1345 for RSV?
• What are the forecasted sales of mRNA-1345 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to mRNA-1345 for RSV?
• Which are the late-stage emerging therapies under development for the treatment of RSV?

This product will be delivered within 2 business days.